Biz Briefs
Read More »
Money
Global Crossing to Buy Impsat for 95 Million
Global Crossing agrees to acquire Impsat for $95 million, or $9.32 a share.
Read More »DOV Pharmaceutical Gets Booted from the NASDAQ
DOV Pharmaceutical has been delisted from the NASDAQ effective tomorrow at the start of business.
Read More »VaxInnate Secures 40 Million in Series C Financing
Cranbury-based drug manufacturer VaxInnate says it secured $40 million in Series C financing.
Read More »Vornado Partners with Gale International
Vornado Realty Trust in Paramus entered a 50/50 joint venture with New York-based Gale International to redevelop property to be bought from Federated Department Stores
Read More »High-Flyers Fall
Experts see little industry-wide impact from the collapse of Kara Homes
Read More »Cambrex Sells Two of Three Subsidiaries for 460 Million Cash
Life sciences company Cambrex in East Rutherford entered into a stock purchase agreement for the sale of its biopharma and bioproducts subsidiaries to Swiss life sciences company Lonza Group for $460 million cash
Read More »Barr Finalizes PLIVA Purchase
Barr Pharmaceuticals in Woodcliff Lake completes its purchase of Croatia-based PLIVA
Read More »Chubb Aims to Ward Off Insurance Claims
Infrared technology typically used on commercial properties enters luxury home market
Read More »Blogging Lawyers Face Regulatory Scrutiny
Industry Report
Read More »Arbinet Explores Possible Sale or Merger
New Brunswick-based Arbinet (NASDAQ:ARBX) is looking at a number of options to increase its value to its shareholders. These include revising its business plan and selling or merging the company. Shares of Arbinet were up $0.11 to $5.26 in early afternoon trading.
Read More »Taking Charge of a Local Big-Four Accounting Office
The NJBIZ Interview - Thomas Duffy
Read More »